Edition:
India

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

85.26USD
23 May 2018
Change (% chg)

$0.29 (+0.34%)
Prev Close
$84.97
Open
$84.54
Day's High
$86.16
Day's Low
$84.51
Volume
1,096,365
Avg. Vol
1,346,130
52-wk High
$89.71
52-wk Low
$76.42

Latest Key Developments (Source: Significant Developments)

Medtronic Announces FDA Approval Of Infuse Bone Graft In New Spine Surgery Indications
Monday, 30 Apr 2018 

April 30 (Reuters) - Medtronic PLC ::MEDTRONIC ANNOUNCES FDA APPROVAL OF INFUSE(TM) BONE GRAFT IN NEW SPINE SURGERY INDICATIONS USING PEEK INTERBODY IMPLANTS.  Full Article

Medtronic In.Pact Admiral Drug Coated Balloon Receives FDA Approval
Monday, 23 Apr 2018 

April 23 (Reuters) - Medtronic PLC ::MEDTRONIC IN.PACT(TM) ADMIRAL(TM) DRUG COATED BALLOON RECEIVES FDA APPROVAL TO TREAT LONG SFA LESIONS.MEDTRONIC PLC - APPROVAL WAS BASED ON CLINICAL DATA FROM COMPLEX LESION IMAGING COHORTS OF IN.PACT GLOBAL STUDY.  Full Article

Medtronic Announces U.S. Launch Of Optisphere Embolization Spheres
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Medtronic PLC ::MEDTRONIC - ANNOUNCES U.S. LAUNCH OF OPTISPHERE EMBOLIZATION SPHERES, A RESORBABLE EMBOLIC PLATFORM DESIGNED FOR EMBOLIZATION OF HYPERVASCULAR TUMORS.  Full Article

Medtronic Gets FDA Approval For Guardian Connect CGM System For People With Diabetes
Monday, 12 Mar 2018 

March 12 (Reuters) - Medtronic Plc ::MEDTRONIC RECEIVES FDA APPROVAL FOR GUARDIAN CONNECT CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM FOR PEOPLE LIVING WITH DIABETES.SAYS ‍GUARDIAN CONNECT SYSTEM WILL BE AVAILABLE IN Q1 OF CO'S FISCAL YEAR 2019​.  Full Article

Medtronic PLC Says ‍Approved Fiscal Year 2018 Q4 Cash Dividend Of $0.46/Ordinary Share
Friday, 9 Mar 2018 

March 9 (Reuters) - Medtronic Plc ::MEDTRONIC PLC - ‍APPROVED FISCAL YEAR 2018 Q4 CASH DIVIDEND OF $0.46/ORDINARY SHARE, REPRESENTING 7% INCREASE OVER PRIOR YEAR​.  Full Article

U.S. FDA Says Medtronic Recalls Certain Types Of Defibrillators
Tuesday, 27 Feb 2018 

Feb 26 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS MEDTRONIC RECALLS CARDIAC RESYNCHRONIZATION THERAPY AND IMPLANTABLE CARDIOVERTER DEFIBRILLATORS DUE TO MANUFACTURING ERROR.U.S. FDA SAYS RECALLED 48 UNITS IN U.S. OF MEDTRONIC'S CARDIAC RESYNCHRONIZATION THERAPY WITH DEFIBRILLATION AND IMPLANTABLE CARDIOVERT-DEFIBRILLATORS.U.S. FDA SAYS IDENTIFIED MEDTRONIC'S ICDS, CRT-DS RECALL AS A CLASS I RECALL; USE OF THESE DEVICES MAY CAUSE SERIOUS INJURIES OR DEATH.  Full Article

Medtronic Receives FDA Clearance For Riptide Aspiration System
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Medtronic Plc ::MEDTRONIC RECEIVES FDA CLEARANCE FOR RIPTIDE(TM) ASPIRATION SYSTEM.MEDTRONIC SAYS UNIT RECEIVED U.S. FDA CLEARANCE OF RIPTIDE ASPIRATION SYSTEM.  Full Article

FDA Approves Innovative Clinician Programmer For The Medtronic Synchromed II Intrathecal Drug Delivery System
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Medtronic Plc ::FDA APPROVES INNOVATIVE CLINICIAN PROGRAMMER FOR THE MEDTRONIC SYNCHROMED II INTRATHECAL DRUG DELIVERY SYSTEM FOR CHRONIC PAIN AND SEVERE SPASTICITY.  Full Article

Medtronic reports Q2 non-GAAP earnings per share of $1.07
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Medtronic Plc :Medtronic reports second quarter financial results.Q2 non-GAAP earnings per share $1.07.Q2 GAAP earnings per share $1.48.Q2 earnings per share view $0.98 -- Thomson Reuters I/B/E/S.Medtronic Plc - ‍company reiterates full year revenue and EPS guidance​.Medtronic Plc - qtrly ‍revenue of $7.1 billion​.Q2 revenue view $6.93 billion -- Thomson Reuters I/B/E/S.Medtronic plc qtrly ‍CVG worldwide revenue of $2.773 billion increased 7 percent on both a reported and constant currency basis​.Medtronic plc qtrly ‍RTG worldwide revenue of $1.863 billion increased 2 percent on both a reported and constant currency basis​.FY2018 earnings per share view $4.68, revenue view $29.36 billion -- Thomson Reuters I/B/E/S.Medtronic Plc qtrly ‍spine revenue of $659 million decreased 1 percent on both a reported and constant currency basis​.Medtronic Plc - ‍in fiscal year 2018, company continues to expect comparable, constant currency revenue growth to be in range of 4 to 5 percent​.Medtronic Plc - "‍Hurricane Maria, in particular, significantly affected our manufacturing operations in Puerto Rico"​ for quarter.  Full Article

Medtronic announces FDA approval and U.S. launch of next generation pacemakers
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Medtronic Plc :Medtronic announces FDA approval and U.S. launch of next generation pacemakers.Medtronic Plc - announces ‍U.S. FDA approval and U.S. commercial launch of portfolio of Azure pacemakers with Bluesync technology​.  Full Article

UPDATE 3-Medtronic beats estimates on cardio, diabetes gains

* Shares up 3 percent (Adds details, analysts' comments, updates share price)